Company Announcement / Press release Archives - Page 12 of 18

Xspray Pharma Contemplates a Directed Share Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Xspray Pharma AB (publ) (“Xspray” or the “Company”) has mandated Citigroup Global Markets […]

Number of shares and votes in Xspray

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of the exercise of warrants under the company's incentive programs. Through the exercise of warrants under the company's incentive program, the number of outstanding shares and votes has increased by 219,632 […]

Xspray announces positive preliminary results from the study for its lead product candidate HyNap-Dasa

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces preliminary results from the second out of two bioequivalence studies in healthy volunteers with its lead product candidate HyNap-Dasa. The study fulfilled statistical and formal bioequivalence requirements for HyNap-Dasa compared to the reference product Sprycel. The study was conducted in healthy volunteers under fed conditions. “I am […]

Michael Wolff Jensen will not stand for re-election as Chairman of Xspray Pharma AB

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the Chairman of the Board, Michael Wolff Jensen, has informed the company that he will not stand for re-election at the 2021 Annual General Meeting (AGM). Michael Wolff Jensen has been Chairman of Xspray Pharma’s Board of Directors since 2013, and will stay as Chairman until […]

Number of shares and votes in Xspray

Xspray announces positive stability data on HyNap-Dasa tablets

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces six months data from its stability study with HyNap-Dasa tablets manufactured in commercial scale. Six months stability data on commercially manufactured HyNap-Dasa demonstrates that the tablets complies with specifications and that they can be used in an upcoming ANDA filing. In February 2020 stability studies were initiated […]

Warrant holders exercise all warrants within the framework of incentive program

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the CEO Per Andersson and other warrant holders have chosen to make full use of the opportunity to subscribe for shares in Xspray by fully exercising their respective number of warrants in the warrant program LTIP 2017/2020. At the same time, Chairman of the Board Michael […]

Xspray strengthens the value of the product portfolio with patent protection for tablet of dasatinib propylene glycol solvate

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding its patent application for tablets containing dasatinib propylene glycol solvate (dasatinib PG). When issued this patent will significantly strengthen Xspray's IP rights and means that any possible future […]

Xspray announces preliminary results from the first study for its lead product candidate HyNap-Dasa

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces preliminary data from the first out of two bioequivalence studies in healthy volunteers with its lead product candidate HyNap-Dasa. The primary aim was to demonstrate bioequivalence for HyNap-Dasa compared to the reference product Sprycel. The first study did not fulfil statistical bioequivalence requirements due to high […]

Xspray enters manufacturing collaboration in Malta

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that Xspray has signed a term sheet with Pharmacare Premium Ltd. for a new manufacturing facility in Malta based on its patented technology platform. The new production lines will be placed within Pharmacare Premium’s existing facility. Apart from increasing Xspray’s manufacturing capacity for amorphous protein kinase inhibitors […]